Advertisement

Topics

Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers

2016-07-29 04:08:21 | BioPortfolio

Summary

The purpose of this study is to determine if using e-cigarettes (ECIG) rather than regular tobacco cigarettes alters lung inflammation in people with HIV. The study is also interested in asking subjects their opinion on the use of ECIG and how they make them feel. This study is for research purposes only and is not intended to treat asthma or HIV or to modify tobacco use.

Description

Title: Effects of e-cigarettes (ECIGs) on pulmonary inflammation and behavior in HIV infected smokers

Purpose of the Study: Even though smoking is the leading cause of preventable disease and deaths in the U.S., millions of Americans continue to smoke cigarettes, including 40-70% of all HIV-infected patients. The advent of e-cigarettes as a potential risk reduction strategy to reduce traditional tobacco cigarette use and promote smoking cessation is attractive. The goal of the proposed research is to gain an understanding of the cellular and inflammatory mechanisms that occur in the lung of HIV-infected smokers who transition from conventional tobacco cigarettes to e-cigarettes and to characterize the effects of substituting e-cigarettes on withdrawal, craving and neurocognition. These efforts will provide first in kind data on the effects of ECIGs in this study population.

Background & Significance: While rates of cigarette smoking are gradually decreasing in the US, the burden of tobacco abuse among people living with HIV remains undisputedly high with prevalence estimates two to three times higher than the general population (42.4% vs. 17.8%). Although ECIGs likely contain significantly fewer numbers of toxicants compared to combustible cigarettes, it is unclear whether ECIG are less harmful than their traditional tobacco counterparts or if they can reduce withdrawal, craving and neurocognitive deficits that precipitate relapse to conventional cigarettes. The biological effects of ECIG on lung health have not yet been sufficiently characterized due the relatively nascent nature of the field. While combustible tobacco use induces oxidant stress in the airways of healthy smokers, little work to date has established the effect of ECIG use on oxidant stress in human airways. Transitioning the HIV-infected smoker from combustible tobacco to ECIG may decrease lung oxidative stress, improve lung function and decrease withdrawal symptoms and deficits in neurocognition commonly seen with tobacco withdrawal.

Design & Procedures: HIV-infected persons will be recruited from the Duke Infectious Diseases Clinic. For this pilot study, 15 willing subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. In order to facilitate participants' successful transition to ECIG, a mobile contingency management (mCM) procedure (discussed below) will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the Duke Clinical Research Unit (DCRU). The first respiratory assessment will occur at study visit 1 (V1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation. Pulmonary assessments will be repeated again 4wks after transition to ECIG or continued UB use (V4). A final respiratory assessment (V5) will occur 2 weeks after stopping ECIG or after 6 weeks of continued UB use to measure changes relative to baseline lung function, oxidative stress, and inflammation. Neuro-cognitive and behavioral visits will occur at respiratory visits as well as 2 weeks after ECIG transition / continued UB use (V3).

Selection of Subjects: Inclusion / Exclusion Criteria are provided below.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Conditions

Lung Inflammation

Intervention

ECIGS, mobile contingency management (mCM), Usual brand

Status

Not yet recruiting

Source

Duke University

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-07-29T04:08:21-0400

Clinical Trials [2905 Associated Clinical Trials listed on BioPortfolio]

Contingency Management Treatment Duration

310 alcohol abusing or dependent patients beginning intensive outpatient day treatment at community-based clinics will be randomly assigned to one of four conditions: (a) standard treatmen...

The Effect of a Contingency Management Intervention on Substance Use

Contingency management interventions involve providing a tangible reward for progress toward treatment goals. The purpose of this study is to determine whether a contingency management int...

Mobile Contingency Management for Smoking Cessation in Returning US Veterans

The primary goal of the study is to evaluate the effectiveness of a combined tele-health and contingency management (CM) intervention that the investigators call mobile CM, or mCM, in prom...

Adding Contingency Management to Treatment as Usual for Disordered Gambling.

The aim of this study is to conduct a trial to investigate the efficacy of adding Contingency Management (CM) to Treatment as Usual (TAU) for the treatment of Disordered Gambling. Results ...

Multi-domain Lifestyle Modification With Contingency Management for Geriatric Depression

To compare the effectiveness of usual care management (UCM) for geriatric depressive symptoms in the community vs newly-developed lifestyle modification with contingency management (LMCM)

PubMed Articles [15969 Associated PubMed Articles listed on BioPortfolio]

A randomized trial of contingency management reinforcing attendance at treatment: Do duration and timing of reinforcement matter?

Contingency management (CM) interventions that reinforce attendance have rarely been evaluated in terms of reducing drug use. Using a sequential randomized design, this study examined the efficacy of ...

Web-Based Contingency Management for Adolescent Tobacco Smokers: A Clinical Trial.

Adolescence is a critical time when the majority of tobacco users initiate smoking. Contingency management for adolescent smoking cessation has shown promise in previous studies, but efficacy followin...

Induction of neutrophil apoptosis by a Bcl-2 inhibitor reduces particulate matter-induced lung inflammation.

Environmental particulate matter exposure can cause various respiratory problems including aggravated asthma, decreased lung function and increased respiratory symptoms. However, the molecular mechani...

Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review.

Stimulant Use Disorders (SUDs) are an emergent public health concern in the United States and worldwide. However, there is still a lack of consensus for best-approaches regarding treatment of SUD. Rec...

Inflammation and primary graft dysfunction after lung transplantation: CT-PET findings.

The leading cause of early mortality after lung transplantation is Primary Graft Dysfunction (PGD). We assessed the lung inflammation, inflation status and inhomogeneities after lung transplantation. ...

Medical and Biotech [MESH] Definitions

A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.

Inflammation of the lung parenchyma that is associated with PLEURISY, inflammation of the PLEURA.

A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.

A complex systemic syndrome with inflammatory and autoimmune components that affect the skin, fascia, muscle, nerve, blood vessels, lung, and heart. Diagnostic features generally include EOSINOPHILIA, myalgia severe enough to limit usual activities of daily living, and the absence of coexisting infectious, autoimmune or other conditions that may induce eosinophilia. Biopsy of affected tissue reveals a microangiopathy associated with diffuse inflammation involving connective tissue. (From Spitzer et al., J Rheumatol Suppl 1996 Oct;46:73-9; Blackburn WD, Semin Arthritis Rheum 1997 Jun;26(6):788-93)

Coverage by contract whereby one part indemnifies or guarantees another against loss by a specified contingency.

More From BioPortfolio on "Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...


Searches Linking to this Trial